Mosapride stimulates human 5-HT4-serotonin receptors in the heart
Open Access
- 18 March 2024
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (9) , 6705-6720
Abstract
Mosapride (4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl) methyl]-2-morpholinyl]-methyl] benzamide) is a potent agonist at gastrointestinal 5-HT4 receptors. Mosapride is an approved drug to treat several gastric diseases. We tested the hypothesis that mosapride also stimulates 5-HT4 receptors in the heart. Mosapride increased the force of contraction and beating rate in isolated atrial preparations from mice with cardiac overexpression of human 5-HT4-serotonin receptors (5-HT4-TG). However, it is inactive in wild-type mouse hearts (WT). Mosapride was less effective and potent than serotonin in raising the force of contraction or the beating rate in 5-HT4-TG. Only in the presence of cilostamide (1 μM), a phosphodiesterase III inhibitor, mosapride, and its primary metabolite time dependently raised the force of contraction under isometric conditions in isolated paced human right atrial preparations (HAP, obtained during open heart surgery). In HAP, mosapride (10 μM) reduced serotonin-induced increases in the force of contraction. Mosapride (10 µM) shifted the concentration–response curves to serotonin in HAP to the right. These data suggest that mosapride is a partial agonist at 5-HT4-serotonin receptors in HAP.Keywords
Funding Information
- Martin-Luther-Universität Halle-Wittenberg
This publication has 30 references indexed in Scilit:
- Lysergic acid diethylamide stimulates cardiac human H2 histamine and cardiac human 5-HT4-serotonin receptorsNaunyn-Schmiedeberg's Archives of Pharmacology, 2023
- Cardiovascular effects of bufotenin on human 5-HT4 serotonin receptors in cardiac preparations of transgenic mice and in human atrial preparationsNaunyn-Schmiedeberg's Archives of Pharmacology, 2023
- Functional interaction of H2-receptors and 5HT4-receptors in atrial tissues isolated from double transgenic mice and from human patientsNaunyn-Schmiedeberg's Archives of Pharmacology, 2021
- Which phosphodiesterase can decrease cardiac effects of 5-HT4 receptor activation in transgenic mice?Naunyn-Schmiedeberg's Archives of Pharmacology, 2019
- Cardiovascular effects of cisapride and prucalopride on human 5-HT4 receptors in transgenic miceNaunyn-Schmiedeberg's Archives of Pharmacology, 2018
- Effect of mosapride on Kv4.3 potassium channels expressed in CHO cellsNaunyn-Schmiedeberg's Archives of Pharmacology, 2013
- Human 5-HT4 receptor stimulation in atria of transgenic miceNaunyn-Schmiedeberg's Archives of Pharmacology, 2013
- Phosphorylation of phospholamban and troponin I through 5-HT4 receptors in the isolated human atriumNaunyn-Schmiedeberg's Archives of Pharmacology, 2008
- Influence of mosapride citrate on gastric motility and autonomic nervous function: evaluation by spectral analyses of heart rate and blood pressure variabilities, and by electrogastrographyJournal of Gastroenterology, 2002
- Targeted Overexpression of Phospholamban to Mouse Atrium Depresses Ca2+Transport and ContractilityJournal of Molecular and Cellular Cardiology, 1998